ArticleCureus2025
Late-Onset Thyroid Hormone Resistance Following Total Thyroidectomy for Papillary Thyroid Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid hormone resistance (RTH) is a rare disorder characterized by impaired cellular responsiveness to thyroid hormones, leading to discordant thyroid function tests and varied clinical manifestations. We present the case of a 43-year-old Cuban-American female patient who presented with dizziness, vertigo, repeated falls, and a severe headache following a minor fall. Additional symptoms included nausea, vomiting, photophobia, cold intolerance, generalized body aches, and fatigue. Her medical history was significant for total thyroidectomy for papillary thyroid cancer, multiple sclerosis (MS), pituitary macroadenoma, Cushing's disease, and polycystic ovary syndrome (PCOS). Post-thyroidectomy, she remained on high-dose levothyroxine (400-750 mcg daily). However, laboratory tests showed persistently elevated thyroid-stimulating hormone (TSH) levels, hence raising suspicion for RTH. This case highlights the challenges of diagnosing and managing RTH, a rare endocrine disorder often resulting from mutations in the thyroid hormone receptor-beta (THB) gene. RTH is characterized by inappropriately normal or elevated TSH despite high thyroid hormone levels, reflecting tissue-level resistance. This case underscores the complexities of identifying RTH in the setting of multiple comorbidities and a history of thyroidectomy. It also emphasizes the need for clinician awareness of atypical presentations of RTH, particularly in patients with extensive endocrine and systemic histories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.